secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001213900-26-004488
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex wins R&D award for obstructive sleep apnea drug IHL-42X
----------------------------------------------------------------

- Recognized in Respiratory Disorders category of 2025 Clinical Trials Arena Excellence Awards.
- IHL-42X is an oral fixed-dose combination (dronabinol + acetazolamide) for moderate-to-severe OSA.
- Award highlights Incannex's research-driven approach to address unmet needs in device-based therapy non-adherence.
- CEO Joel Latham states award underscores science-driven approach as IHL-42X advances into late-stage development.
- Company also progressing pipeline programs IHL-675A (rheumatoid arthritis) and PSX-001 (anxiety).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026004488/0001213900-26-004488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026004488/ea0272884-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-004488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer